New research has uncovered a complex interplay between extracellular matrix (ECM) structure and the transcriptional responses of cancer cells, showing how they alter their gene expression to ‘escape’ from ECM. The findings will make it easier to identify tumors that are likely to metastasize at an early stage.
Bsense Bio Therapeutics Ltd. has disclosed new potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators and transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists reported to be useful for the treatment of neuropathic pain, pruritus and tinnitus.
Neumora Therapeutics Inc. has patented NMDA receptor positive allosteric modulators reported to be useful for the treatment of autoimmune disease, infections, neurological and psychiatric disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new benzimidazoles acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of rheumatoid arthritis, metabolic dysfunction-associated steatohepatitis (MASH), giant cell arteritis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
Apogee Pharmaceuticals Inc. has prepared fatty acid amide hydrolase (FAAH) inhibitors reported to be useful for the treatment of cancer, pain, inflammation, anxiety and mood disorders, cardiovascular disorders, autoimmune diseases and neurological disorders, among others.
The boronic acid transition state inhibitors S-02030 and MB-076 were strategically designed to be active against cephalosporinases and carbapenemases, especially KPC (Klebsiella pneumoniae carbapenemase).
Prostate cancer is still one of the main causes of cancer death among men; while prostate-specific antigen (PSA) testing is done for screening, there are recommendations against its use due to its nonspecific and suboptimal results. There is thus an urgent need for new biomarkers that are more accurate in the detection of prostate cancer.
Mair Therapeutics BV has launched with pre-seed funding from Torrey Pines Investment and Oost NL and with a focus on developing treatments for neurodegenerative disorders, particularly Parkinson’s disease.
RSS
